secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078577
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma provides IBA101 strategic update targeting PD-1/L1 patent cliff partnership opportunities
--------------------------------------------------------------------------------

- IBA101 is a CD47 mAb designed to avoid RBC/platelet binding, eliminating cytopenia that derailed Hu5F9 and lemzoparlimab.
- Preclinical data shows IBA101 + anti-PD-1 combination produces synergistic anti-tumor response with favorable safety.
- Company claims it is the only U.S.-based firm developing a CD47 blocker with a validated safety profile.
- PD-1/L1 inhibitors Keytruda (Merck) and Opdivo (BMS) face core patent expiry by 2028; others (Tecentriq, Imfinzi, Libtayo) by 2030.
- Strategy positions IBA101 as a patent-protected synergistic partner to extend PD-1/L1 franchise lifecycles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925078577/0001104659-25-078577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925078577/tm2523534d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer